JP4295951B2 - 活性成分の制御型溶解 - Google Patents

活性成分の制御型溶解 Download PDF

Info

Publication number
JP4295951B2
JP4295951B2 JP2002106400A JP2002106400A JP4295951B2 JP 4295951 B2 JP4295951 B2 JP 4295951B2 JP 2002106400 A JP2002106400 A JP 2002106400A JP 2002106400 A JP2002106400 A JP 2002106400A JP 4295951 B2 JP4295951 B2 JP 4295951B2
Authority
JP
Japan
Prior art keywords
exchange resin
resin
complex
meq
capacity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002106400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003012562A (ja
JP2003012562A5 (https=
Inventor
リン・ヒューズ
サイモン・アンドリュー・ベラミー
クリスティーナ・ハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rohm and Haas Co
Original Assignee
Rohm and Haas Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohm and Haas Co filed Critical Rohm and Haas Co
Publication of JP2003012562A publication Critical patent/JP2003012562A/ja
Publication of JP2003012562A5 publication Critical patent/JP2003012562A5/ja
Application granted granted Critical
Publication of JP4295951B2 publication Critical patent/JP4295951B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002106400A 2001-04-09 2002-04-09 活性成分の制御型溶解 Expired - Lifetime JP4295951B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28244301P 2001-04-09 2001-04-09
US60/282443 2001-04-09

Publications (3)

Publication Number Publication Date
JP2003012562A JP2003012562A (ja) 2003-01-15
JP2003012562A5 JP2003012562A5 (https=) 2005-09-15
JP4295951B2 true JP4295951B2 (ja) 2009-07-15

Family

ID=23081541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002106400A Expired - Lifetime JP4295951B2 (ja) 2001-04-09 2002-04-09 活性成分の制御型溶解

Country Status (6)

Country Link
US (1) US7153497B2 (https=)
EP (1) EP1250937B1 (https=)
JP (1) JP4295951B2 (https=)
KR (1) KR100905453B1 (https=)
DE (1) DE60232290D1 (https=)
TW (1) TWI242446B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115529A1 (en) * 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
CN102488652B (zh) 2006-03-16 2014-06-18 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
CA2689101C (en) * 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
FR2947276B1 (fr) 2009-06-24 2012-10-26 Seppic Sa Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
EP2725072B1 (en) 2012-10-25 2015-07-22 Rohm and Haas Company Aldehyde abatement with porous amine functional resins
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CN111094473B (zh) 2017-07-11 2021-05-07 陶氏环球技术有限责任公司 水性分散体和包含其的水性涂料组合物
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1585174A (en) * 1976-06-16 1981-02-25 Ici Ltd Separation of sugars from mixtures
CH655507B (https=) * 1983-01-12 1986-04-30
US4898729A (en) * 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
JP2003012562A (ja) 2003-01-15
EP1250937B1 (en) 2009-05-13
KR100905453B1 (ko) 2009-07-02
EP1250937A2 (en) 2002-10-23
TWI242446B (en) 2005-11-01
US7153497B2 (en) 2006-12-26
DE60232290D1 (de) 2009-06-25
US20020146384A1 (en) 2002-10-10
EP1250937A3 (en) 2003-09-24
KR20020079473A (ko) 2002-10-19

Similar Documents

Publication Publication Date Title
JP4295951B2 (ja) 活性成分の制御型溶解
US12605333B2 (en) Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
ES2743130T3 (es) Composición farmacéutica
Guo et al. Ion-exchange resins as drug delivery carriers
ES2378573T3 (es) Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
US4221778A (en) Prolonged release pharmaceutical preparations
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
RU2256442C2 (ru) Потребляемая пленка, предназначенная для держания во рту, и способ получения потребляемой пленки
Arafat Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review
JPH04210919A (ja) ピモベンダン経口投与製剤
Elder Pharmaceutical applications of ion-exchange resins
US20060134148A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
EP2329813A1 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
JPS6335527A (ja) 被覆性イオン交換樹脂
US20020176842A1 (en) Extended release of active ingredients
EP0563294A1 (en) Polyamine drug-resin complexes
DK150534B (da) Fremgangsmaade til fremstilling af et farmaceutisk praeparat med forsinket afgivelse af en aktiv bestanddel
JP2008546835A (ja) 複数の活性薬物−樹脂抱合体
EP2361611A2 (en) Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
CN105705166A (zh) 基于丙酸的控释药物组合物
RU2447884C2 (ru) Фармацевтический состав с контролируемым высвобождением действующего вещества
Khan Oral Controlled Release Liquid Dosage Forms (Reconstitutable Powder) by Ion Exchange Resins
Muzammil et al. Ion Exchange Resins for Clinical Applications
Jadhav et al. Ion exchange resins: a novel way to solve formulation problems
Thakor et al. Development and evaluation of osmotic drug delivery system for calcium channel blocker drug

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050405

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20061017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090226

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090323

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090413

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4295951

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120417

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130417

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130417

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140417

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S802 Written request for registration of partial abandonment of right

Free format text: JAPANESE INTERMEDIATE CODE: R311802

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term